Bridge to acquisition

Alzheimer's play Satori gets $15M in debt to reach IND, strategic deal

Bridge to acquisition

First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is betting that its more selective gamma secretase modulator

Read the full 250 word article

How to gain access

Continue reading with a
two-week free trial.